Prosecution Insights
Last updated: November 04, 2026
Application No. 17/995,020

METHODS FOR TREATING VIRAL INFECTIONS WITH NAFAMOSTAT

Non-Final OA §102§103§112
Filed
Sep 29, 2022
Priority
Mar 31, 2020 — provisional 63/003,061 +2 more
Examiner
TOWNSLEY, SARA ELIZABETH
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ensysce Biosciences Inc.
OA Round
3 (Non-Final)
26%
Grant Probability
At Risk
3-4
OA Rounds
0m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants only 26% of cases
26%
Career Allowance Rate
105 granted / 401 resolved
-33.8% vs TC avg
Strong +48% interview lift
Without
With
+48.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
74 currently pending
Career history
468
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
41.7%
+1.7% vs TC avg
§102
18.1%
-21.9% vs TC avg
§112
26.5%
-13.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 401 resolved cases

Office Action

§102 §103 §112
NON-FINAL REJECTION Receipt is acknowledged of Applicants' Amendments and Remarks, filed Jun. 4, 2026. Claims 1, 16, and 35 have been amended. Claims 5, 8, 9, 14, 15, 27, 28, 33, 34, 36, and 37 have been canceled. New claims 38-40 have been added. Thus, claims 1-4, 6, 7, 10-13, 16-26, 29-32, 35, and 38-40 now represent all claims currently pending and under consideration. Rejections and/or objections not reiterated from previous Office Actions are hereby withdrawn. The rejections and/or objections set forth below are either maintained or newly applied, and constitute the complete set presently applied to the instant claims. REQUEST FOR CONTINUED EXAMINATION A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on Jun. 4, 2026 has been entered. INFORMATION DISCLOSURE STATEMENT The information disclosure statement (IDS) submitted on Jun. 23, 2026 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner. RESPONSE TO AMENDMENTS & ARGUMENTS The amendments to the claims filed Jun. 4, 2026 overcome the rejection under 35 U.S.C. § 103 over Irie et al., Hanazawa et al., and Oishi. Therefore, the rejection has been withdrawn. However, upon further consideration, new grounds of rejection are set forth below. PRIORITY Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. § 112(a) as follows: The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of 35 U.S.C. 112(a) or the first paragraph of pre-AIA 35 U.S.C. 112, except for the best mode requirement. See Transco Products, Inc. v. Performance Contracting, Inc., 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994). The disclosure of the prior-filed application, Provisional Application No. 63/003,061 (filed Mar. 31, 2020) fails to provide adequate support or enablement in the manner provided by 35 U.S.C. 112(a) for one or more claims of this application. Newly amended independent claim 1 is drawn to a method of treating a viral infection in a subject comprising orally administering a modified release solid oral dosage form comprising a therapeutically effective amount of nafamostat or a pharmaceutically acceptable salt thereof to the subject in need thereof, wherein the amount of nafamostat measurable in the plasma of the subject after 1 to 8 hours after administering is below about 5 ng/mL and wherein the oral administration delivers the nafamostat or a pharmaceutically acceptable salt thereof to the gastrointestinal (GI) tract and is effective to reduce viral load in the gastrointestinal tract without achieving a therapeutically effective systemic plasma concentration. Newly amended independent claim 16 is drawn to a method of inhibiting a viral infection in a subject, comprising orally administering a modified release solid oral dosage form comprising a therapeutically effective amount of nafamostat or a pharmaceutically acceptable salt thereof, wherein the amount of nafamostat measurable in the plasma of the subject after 1 to 8 hours after administering is below about 5 ng/mL and wherein the oral administration delivers the nafamostat or salt thereof to the gastrointestinal (GI) tract without achieving a therapeutically effective systemic plasma concentration. Independent claim 35 is drawn to a method of reducing the risk of experiencing an adverse event associated with intravenous administration of nafamostat mesylate in a subject having a viral infection comprising orally administering a modified release solid oral dosage form comprising a therapeutically effective amount of nafamostat mesylate to the subject, and wherein the amount of nafamostat measurable in the plasma of the subject after 1 to 8 hours after administering is below about 5 ng/mL. While provisional application 63/003,061 defines modified release pharmaceutical compositions (para. [0035]), and discloses that the claimed compositions can be modified release formulations (paras. [0069], [0075], [0076], [0078]), 63/003,061 fails to exemplify any solid oral dosage form; any method of administering a solid oral dosage form to a subject to treat or inhibit a viral infection; or any risk reduction relative to i.v. administration. Specifically, the ‘061 provisional application discloses three examples. Example 1 discloses the preparation of a drinkable aqueous liquid formulation comprising nafamostat mesylate, succinic acid, and D-mannitol. Example 2 is a prophetic example of administering the drinkable aqueous liquid formulation of Example 1 to “infected subjects,” without specifying the nature of the infection, and with no experimental results reported. Example 3 is a prophetic example of the beneficial effects in the treatment group of Example 2 as compared to control, with no experimental results reported. Thus, provisional application 63/003,061 fails to exemplify any modified-release or solid dosage forms; any methods of treating or inhibiting a viral infection in a subject; or any reduction of risk of an adverse event associated with intravenous administration of nafamostat mesylate by oral administration, as recited by the independent claims. In addition, in the Remarks filed Jun. 4, 2026, Applicant argues that “the amended claims now require more than mere oral administration – they require a modified release dosage form. A modified release formulation represents a deliberate pharmaceutical design choice that controls the rate, timing, and location of drug release within the GI tract. This is fundamentally different from the oral solutions of the specification's Examples” (¶ 1, p. 7; emphasis added). Thus, Provisional Application No. 63/003,061 fails to provide adequate support or enablement in the manner required by 35 U.S.C. § 112(a) for the newly amended claims. NEW REJECTIONS Claim Rejections - 35 USC § 112(b) – Indefiniteness The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-4, 6, 7, 10-13, 16-26, 29-32, 35, and 38-40 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. As recognized by MPEP § 2173.05(g), when claims merely recite a description of a problem to be solved or a function or result achieved by the invention, the boundaries of the claim scope may be unclear. Here, independent claims 1, 16, and 35 are drawn to methods of administering a modified release solid oral dosage form comprising a therapeutically effective amount of nafamostat or a pharmaceutically acceptable salt thereof, wherein the amount of nafamostat measurable in the plasma of the subject after 1 to 8 hours after administering is below about 5 ng/mL; wherein the oral administration delivers the nafamostat or pharmaceutically acceptable salt thereof to the gastrointestinal (GI) tract; and is effective to reduce viral load in the gastrointestinal tract without achieving a therapeutically effective systemic plasma concentration. These limitations recite the intrinsic physiological effects that allegedly occur or naturally flow from carrying out the active method step of administering to a subject with a viral infection a modified release solid oral dosage form comprising a therapeutically effective amount of nafamostat or a pharmaceutically acceptable salt thereof. As detailed in the final action dated Apr, 1, 2026 (pp. 10-12), the specification itself establishes that oral administration of nafamostat inherently results in delivery of nafamostat locally to the GI tract, which reduces the GI viral load and treats a viral infection via that GI-localized delivery; and inherently results in a plasma concentration of nafamostat at 1-8 hours post-dose below about 5 ng/ml. This is why nafamostat is usually administered intravenously rather than orally, when used to treat other indications. There is no evidence in the specification or in the prior art that the particular dosage form of orally administered nafamostat is critical: it is the oral route of administration itself that delivers nafamostat to the GI tract and reduces viral load in the GI tract without achieving a therapeutically effective plasma concentration, regardless of how it is formulated. Thus, these limitations merely recite the intrinsic results of orally administering nafamostat to a subject to treat a viral infection, and as such, are not limiting. As recognized by MPEP § 2111.04, claim scope is not limited by claim language that does not require steps to be performed, or by claim language that does not limit a claim to a particular structure. The above-cited “wherein” clauses simply describe what the active step of administering a modified release solid oral dosage form is supposed to accomplish, and thus fail to further limit the scope of independent claims 1, 16, and 35, and claims dependent thereon. "A whereby clause in a method claim is not given weight when it simply expresses the intended result of a process step positively recited." Hoffer v. Microsoft Corp., 405 F.3d 1326, 1329, 74 USPQ2d 1481, 1483 (Fed. Cir. 2005). Thus, for examination purposes, the claimed physiological results and/or effects of administering the claimed dosage forms are construed as intended use limitations and are given no patentable weight. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-4, 6, 7, 10-13, 16-20, 24-26, 29-32, and 38-40 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Choi (WO 2022/065789, cited on PTO-892). Choi discloses oral formulations in a sustained release form or a controlled release form, comprising nafamostat or a pharmaceutically acceptable salt thereof and a water-soluble sustained-release polymer (abstract). The formulations can efficiently control the release rate (or dissolution rate) of nafamostat or salt thereof, and are useful as an antiviral pharmaceutical composition for treating or preventing coronavirus infection (COVID-19) (para. [0014]). The formulations of Choi are exemplified in the form of a tablet (a solid dosage form) (Examples 1-20), prepared by wet granulation, dry granulation, or direct tableting (para. [0033]). Thus, Choi discloses a method of treating or preventing a viral infection in a subject comprising orally administering a modified-release solid oral dosage form comprising a therapeutically effective amount of nafamostat or a salt thereof to a subject in need thereof, as recited by claims 1-3, 6, 17-20, 24, 25, and 40. Choi exemplifies modified-release oral tablets comprising 100 mg nafamostat mesylate (Examples 1-5), which falls within the range of about 50 mg to about 200 mg of nafamostat mesylate, as recited by claim 7. The formulations of Choi may contain nafamostat or a pharmaceutically acceptable salt thereof in an amount ranging from 10 to 200 mg per unit formulation, e.g., 10, 20, 30, 50, 75, 100, 150, or 200 mg, and may be in a form administered orally once a day (para. [0022]); or in an amount ranging from 30 to 600 mg per unit formulation and may be administered orally three times a day (para. [0020]), which reads on: a total daily dose administered of about 100 mg to about 1500 mg of nafamostat mesylate, as recited by claim 4; about 50 mg to about 500 mg nafamostat mesylate administered once, twice, or three times per day, as recited by claim 10; at least about 0.1 mg/kg/day nafamostat mesylate, as recited by claims 11 and 30; about 0.75 mg/kg/day to about 20 mg/kg/day, as recited by claims 12 and 31; and about 1 mg/kg/day to about 10 mg/kg/day, as recited by claims 13 and 32; about 50 mg to about 600 mg of nafamostat mesylate or an equivalent amount of nafamostat or a salt thereof, as recited by claim 26; and in an amount equivalent to about 200 mg to about 500 mg nafamostat mesylate once, twice, or three times per day to the subject, as recited by claim 29. The oral formulations of Choi are disclosed for preventing or treating Coronavirus Disease-19 (COVID-19), caused by infection with the SARS-CoV-2 coronavirus. Choi teaches that the oral formulations exhibit antiviral activity by degrading the TMPRSS2 enzyme protein, which helps the coronavirus bind to ACE2 when entering a host cell (paras. [0007], [0040]). Thus, Choi discloses a method of inhibiting a viral infection in a subject comprising orally administering a modified release solid oral dosage form comprising a therapeutically effective amount of nafamostat or a salt thereof, as recited by independent claim 16.. For the foregoing reasons, Choi anticipates claims 1-4, 6, 7, 10-13, 16-20, 24-26, 29-32, and 38-40. Claim Rejections - 35 U.S.C. § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-4, 6, 7, 10-13, 16-26, 29-32, 35, and 40 are rejected under 35 U.S.C. § 103 as being unpatentable over Choi (WO 2022/065789, cited on PTO-892). Choi discloses oral formulations in a sustained release form or a controlled release form, comprising nafamostat or a pharmaceutically acceptable salt thereof and a water-soluble sustained-release polymer (abstract). The formulations can efficiently control the release rate (or dissolution rate) of nafamostat or salt thereof, and are useful as an antiviral pharmaceutical composition for treating or preventing coronavirus infection (COVID-19) (para. [0014]). The formulations of Choi are exemplified in the form of a tablet (a solid dosage form) (Examples 1-20), prepared by wet granulation, dry granulation, or direct tableting (para. [0033]). Thus, Choi discloses a method of treating or preventing a viral infection in a subject comprising orally administering a modified-release solid oral dosage form comprising a therapeutically effective amount of nafamostat or a salt thereof to a subject in need thereof, as recited by claims 1-3, 6, 17-20, 24, 25, and 40. Choi exemplifies modified-release oral tablets comprising 100 mg nafamostat mesylate (Examples 1-5), which falls within the range of about 50 mg to about 200 mg of nafamostat mesylate, as recited by claim 7. The formulations of Choi may contain nafamostat or a pharmaceutically acceptable salt thereof in an amount ranging from 10 to 200 mg per unit formulation, e.g., 10, 20, 30, 50, 75, 100, 150, or 200 mg, and may be in a form administered orally once a day (para. [0022]); or in an amount ranging from 30 to 600 mg per unit formulation and may be administered orally three times a day (para. [0020]), which reads on: a total daily dose administered of about 100 mg to about 1500 mg of nafamostat mesylate, as recited by claim 4; about 50 mg to about 500 mg nafamostat mesylate administered once, twice, or three times per day, as recited by claim 10; at least about 0.1 mg/kg/day nafamostat mesylate, as recited by claims 11 and 30; about 0.75 mg/kg/day to about 20 mg/kg/day, as recited by claims 12 and 31; and about 1 mg/kg/day to about 10 mg/kg/day, as recited by claims 13 and 32; about 50 mg to about 600 mg of nafamostat mesylate or an equivalent amount of nafamostat or a salt thereof, as recited by claim 26; and in an amount equivalent to about 200 mg to about 500 mg nafamostat mesylate once, twice, or three times per day to the subject, as recited by claim 29. The oral formulations of Choi may be administered once or several times a day, which may be adjusted according to the form of the formulation, the patient's age, weight, gender, pathological condition, food, responsiveness, etc., and a person skilled in the art may appropriately adjust the content of nafamostat or salt thereof per unit formulation and the frequency of administration (para. [0022]). This implicitly discloses the patient population aged 65 or older, as recited by claim 21; and patient populations with a pathological condition as recited by claims 22-23. The oral formulations of Choi are disclosed for preventing or treating Coronavirus Disease-19 (COVID-19), caused by infection with the SARS-CoV-2 coronavirus. Choi teaches that the oral formulations exhibit antiviral activity by degrading the TMPRSS2 enzyme protein, which helps the coronavirus bind to ACE2 when entering a host cell (paras. [0007], [0040]). Thus, Choi discloses a method of inhibiting a viral infection in a subject comprising orally administering a modified release solid oral dosage form comprising a therapeutically effective amount of nafamostat or a salt thereof, as recited by independent claim 16; and wherein the administering occurs before a symptom of a viral infection is observed in the subject, as recited by claim 17. Choi disclose that intravenous administration of nafamostat may risk contamination or infection in the process of dissolution or administration process (para. [0006]). Thus, Choi implicitly discloses that orally administering a modified release solid oral dosage form comprising a therapeutically effective amount of nafamostat mesylate reduces the risk of an adverse event associated with intravenous administration of nafamostat mesylate in a subject having a viral infection, as recited by independent claim 35. It would have been predictable to an ordinarily skilled clinician as of the filing date to modify the methods of Choi by administering a modified release solid oral dosage form to treat a viral infection in patients over age 65, patients with cancer, or immunocompromised patients, as recited by claims 21-23, or to reduce the risk of adverse events, as recited by claim 35, with a reasonable expectation of success, because patients of all ages and underlying conditions are susceptible to viral infections and side effects of systemic administration; and Choi teaches that administration may be adjusted according to the patient's age or pathological condition. A skilled artisan routinely selects and adjusts the optimal treatment protocol for a given patient population, e.g., to enhance patient compliance, which can be modified by routine experimentation. Claim Objections Applicant is advised that should claims 11-13 be found allowable, claims 30-32 will be objected to under 37 CFR 1.75 as being substantial duplicates thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 608.01(m). Citation of Additional Prior Art Additional references made of record are considered pertinent to applicant's disclosure: WO 2021/261837 and WO 2022/080798 (cited on PTO-892). CONCLUSION No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARA E. TOWNSLEY whose telephone number is (571)270-7672. The examiner can normally be reached on 10:00 am - 6:00 pm (ET) M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JEFF S. LUNDGREN can be reached on 571-272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SARA E. TOWNSLEY/Examiner, Art Unit 1629
Read full office action

Prosecution Timeline

Sep 29, 2022
Application Filed
Jun 17, 2025
Non-Final Rejection mailed — §102, §103, §112
Dec 17, 2025
Response Filed
Apr 01, 2026
Final Rejection mailed — §102, §103, §112
Jun 04, 2026
Request for Continued Examination
Jun 05, 2026
Response after Non-Final Action
Oct 28, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12729210
CRYSTAL FORMS OF PYRIDOPYRAZOLE COMPOUNDS AND PREPARATION METHOD THEREFOR
3y 5m to grant Granted Sep 08, 2026
Patent 12692261
SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF
3y 6m to grant Granted Jul 28, 2026
Patent 12662475
DIFLUOROCYCLOHEXYL DERIVATIVES AS IL-17 MODULATORS
3y 8m to grant Granted Jun 23, 2026
Patent 12662483
COCRYSTALLINE FORMS OF FGFR3 INHIBITORS
2y 9m to grant Granted Jun 23, 2026
Patent 12643913
MCL-1 INHIBITOR FORMULATIONS
3y 3m to grant Granted Jun 02, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
26%
Grant Probability
75%
With Interview (+48.4%)
3y 11m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 401 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month